Mobile

A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Biolog...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-000261-38

A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Biologicals’ Engerix™-B (thiomersal-free 20 µg or preservative-free 10 µg) vaccine, in the primary study HBV-280

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the immune response to a challenge dose of hepatitis B vaccine administered in subjects who previously received a complete hepatitis B primary vaccination course, 72 to 78 months ago.

Critère d'inclusion

  • Hepatitis B vaccine challenge dose given to subjects, 17 to 21 years of age, to evaluate immune memory to Hepatitis B antigen, approximately 6 years after priming with Hepatitis B vaccine

Liens